High cost of weight-loss drugs strains state Medicaid programs
The Rising Cost of GLP-1 Drugs: A Statewide Budget Dilemma States across the U.S. are grappling with skyrocketing costs of GLP-1 medications like Wegovy, Ozempic, and Zepbound, designed for weight loss and diabetes treatment. Policymakers are exploring ways to mitigate the financial strain, with Pennsylvania’s Medicaid bracing for a $1.3 billion expenditure in 2025. This … Read more